secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001104659-24-118906
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elutia Q3 net sales $5.9M (-3.3%); EluPro adoption accelerates with 100+ VAC submissions
--------------------------------------------------------------------------------

- Overall Q3 net sales $5.9M, down 3.3% YoY; BioEnvelope sales down 12% to $2.3M as customers await EluPro.
- SimpliDerm sales up 19% to $3.1M; adjusted gross margin improved to 61% from 60%.
- Net income from cont. ops $1.3M driven by $12.7M non-cash warrant revaluation gain; adjusted EBITDA loss $2.9M.
- EluPro: first patient implant, over 100 VAC submissions, 36 accounts ordering; full commercial launch set for Jan 2025.
- Cash balance $25.7M as of Sep 30, 2024, includes $13.8M from warrant exercises in early Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465924118906/0001104659-24-118906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465924118906/tm2428517d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-118906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer